Accès à distance ? S'identifier sur le proxy UCLouvain
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Primary tabs
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès restreint |
Publication date | 2011 |
Language | Anglais |
Journal information | "The Lancet Oncology" - Vol. 12, no.8, p. 773-84 (2011) |
Peer reviewed | yes |
Publisher | TheLancet Publishing Group ((United Kingdom) London) |
issn | 1470-2045 |
e-issn | 1474-5488 |
Publication status | Publié |
Affiliation | UCL - (MGD) Service d'hématologie |
MESH Subject | Adult ; Humans ; Infusion Pumps ; Lymphoma, Follicular ; Male ; Middle Aged ; Neoplasm Staging ; Pyrazines ; Recurrence ; Young Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Agents ; Antineoplastic Combined Chemotherapy Protocols ; Boronic Acids ; Disease-Free Survival ; Female |
Links |
Bibliographic reference | Coiffier, Bertrand ; Osmanov, Evgenii A ; Hong, Xiaonan ; Scheliga, Adriana ; Mayer, Jiri ; et. al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.. In: The Lancet Oncology, Vol. 12, no.8, p. 773-84 (2011) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/133833 |